Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

NMP in Relapsed / Refractory Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02468687
Recruitment Status : Completed
First Posted : June 11, 2015
Last Update Posted : May 5, 2022
Melbourne Health
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia

Brief Summary:
The study will evaluate if the N-methyl-pyrrolidone (NMP) can be safely administered to humans at doses, which induce measurable immunological and anti-tumour effects in patients with myeloma who are resistant to or intolerant of lenalidomide and bortezomib.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: N-methyl-pyrrolidone Phase 1

Detailed Description:
N-Methyl-2-pyrrolidone (NMP) is a small molecule acetyl-lysine mimetic compound with potent (low micromolar range) immunomodulatory and direct anti-myeloma activity attributable to BETbromodomain inhibition at higher concentrations. NMP is nontoxic, stable and already in use as a solvent in biomedical applications. It has been the subject of numerous toxicity studies in humans and been demonstrated to have few adverse effects. The study is proposing an empiric starting dose of 50mg daily, 50% of that seen in healthy volunteers with no observable toxicity. Dose escalation will follow a rule based on accelerated trial design in order to minimise the number of patients treated at sub-therapeutic doses and minimise the length of the study. During the accelerated dose-escalation phase, one patient will be entered per cohort with a dose escalation increment of 100%, with up to 6 dose escalation and up to two dose de-escalation levels.The accelerated phase ends when one patient experiences DLT during the first cycle of treatment or when a total of two patients have experienced moderate toxicity during the first cycle of treatment regardless of the dose level; or the most recent patient has been treated at the highest dose level in the first cycle. If 1 patient experiences a DLT in the first cycle at any dose level, the cohort will be further expanded to a total of 6 patients treated at the same dose level. The maximum tolerated dose (MTD) in the study will be defined as the highest dose in which the incidence of DLT was less than 33%.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label Dose Escalation Trial of Orally Administered N-methyl-pyrrolidone (NMP) in Patients With Relapsed or Refractory Myeloma
Actual Study Start Date : August 20, 2015
Actual Primary Completion Date : October 7, 2021
Actual Study Completion Date : October 7, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
NMP dose escalation in accelerated phase and standard phase
Drug: N-methyl-pyrrolidone
NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
Other Name: NMP

Primary Outcome Measures :
  1. Adverse events to establish the Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]
    Each patient will be monitored for adverse events during the first cycle of NMP treatment (28 days) to establish the maximum tolerated dose

Secondary Outcome Measures :
  1. Optimum biological dose (OBD) [ Time Frame: 6 months ]
    The maximum changes in correlative biomarkers will be tested at the specific time-points. Descriptive statistics will be used to analyse data from correlative studies and summarized in graphical or tabular formats as appropriate.

  2. Safety of the repeated dosing of NMP by oral administration - possible toxicities [ Time Frame: 6 months ]
    To assess safety, the numbers and rates (with confidence intervals) of patients experiencing any haematological and non-haematological and specific grade 3+ adverse events experienced at each given dose level and schedule of NMP will be calculated, over the full treatment period and by cycle

  3. Pharmacokinetic properties of NMP after oral administration [ Time Frame: Predose,0.5,1,2,4,8, 24 hours post dose ]
    Pick plasma concentrations (Cmax) of NMP

  4. Response rate measured using IMWG criteria [ Time Frame: 6 months up to 2 years ]
    Patients will be evaluated for response after every 28 day cycle for the first 6 cycles of treatment and thereafter every 2 months in follow up using the IMWG criteria for multiple myeloma.

  5. Time to progression from start of treatment [ Time Frame: up to 3.5 years ]
    Patients will be assessed for disease progression weekly in Cycle 1, then monthly on D1 of each cycle during treatment for the first 6 months and then monthly until disease progression, next anti-cancer treatment or death. Time to progression from start of treatment will be estimated using Kaplan Meier survival curves.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed diagnosis of plasma cell myeloma defined by WHO 2008 criteria
  2. Measurable disease as defined by at least one of:

    • serum M protein ≥5g/L
    • urine M protein ≥ 200mg/24hrs
    • involved serum free light chain ≥ 100mg/L
    • measurable (by imaging at the discretion of the investigator) soft tissue plasmacytoma
  3. Relapsed, refractory or intolerant of both bortezomib and lenalidomide


  • refractory at least 4 weeks of therapy administered, with less than a partial response by IMWG criteria
  • relapsed from previous response (PR or greater) to therapy, with subsequent disease progression as defined as development of bone marrow dysfunction (fall in Hb of 20g/L or platelet count <100 x 109/L) due to increased bone marrow plasmacytosis
  • OR new lytic bone lesions
  • OR increase in serum M protein of 5g/L
  • OR absolute increase of involved serum free light chain of >250mg/L
  • intolerant: grade 2 or higher toxicity unresponsive to dose adjustment 4. Prior autologous stem cell transplant, unless ineligible for transplant by the discretion of the investigator.

    5. age ≥18 years 6. ECOG performance status <2 7. The following values within 7 days of commencing NMP (blood transfusions prior to study entry are permitted)

  • Haemoglobin >80g/L
  • Absolute neutrophil count >1.0 x 109/L
  • Platelet count ≥ 25 x 109/L
  • Creatinine clearance >30ml/min (by Cockcroft/Gault)
  • Bilirubin ≤ 3x upper limit of normal (ULN)
  • ALT ≤ 3 x ULN
  • Left ventricular ejection fraction (LVEF) ≥45% (by gated cardiac blood pool scan or echocardiography) 9. Life expectancy > 3 months 10. Able to give written informed consent 11. In the opinion of the investigator, willing and able to comply with required study procedures 12. Able to take oral medications (no malabsorptive condition)

Exclusion Criteria:

  1. Pregnant or breastfeeding female patients
  2. Female of child bearing potential unwilling or unable to use two methods of contraception
  3. Received chemotherapy, immunotherapy or biological therapy within two weeks of enrolment. Prednisolone up to 20mg per day permitted for non-myeloma indications.
  4. Patients with a history of another malignancy within 2 years of the baseline visit, excluding treated non-melanotic skin cancer and in-situ carcinoma.
  5. Patients with known CNS involvement unless previously treated and well controlled for a period of ≥3 months AND which do not require the use of steroids.
  6. Uncontrolled intercurrent illness including, but not limited to:

    • Active or uncontrolled infection, including active HIV or viral (A, B or C) hepatitis. NOTE: Patients with controlled infection on antibiotic or antifungal therapy are eligible i.e. the patient should be afebrile for at least 72 hours and be haemodynamically stable.
    • Impaired cardiac function, including any of the following:

      • Myocardial infarction within previous 3 months prior to starting study
      • Symptomatic congestive heart failure (New York Heart Association Class III, IV)
      • Symptomatic coronary artery disease
      • Cardiac arrhythmia not controlled by medication
      • Clinically significant resting bradycardia (<50 beats per minute)
      • Long QT syndrome or a known family history of long QT syndrome or QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
      • Inability to monitor the QT/QTc interval on ECG
      • Other clinically significant uncontrolled heart disease (e.g. unstable angina or uncontrolled hypertension)
    • Impaired hepatic or renal impairment (see inclusion criteria)
    • Uncontrolled diarrhoea, nausea or vomiting
  7. concomitant exposure to another investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02468687

Layout table for location information
Australia, Victoria
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3002
Sponsors and Collaborators
Peter MacCallum Cancer Centre, Australia
Melbourne Health
Layout table for investigator information
Principal Investigator: David Ritchie, Prof Melbourne Health
Layout table for additonal information
Responsible Party: Peter MacCallum Cancer Centre, Australia Identifier: NCT02468687    
Other Study ID Numbers: HREC/14/MH/159
First Posted: June 11, 2015    Key Record Dates
Last Update Posted: May 5, 2022
Last Verified: May 2022
Keywords provided by Peter MacCallum Cancer Centre, Australia:
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases